debt_leverage_profile
Small-cap biotech with modest debt; 20% rate rise marginally increases financing costs but equity dilution risk dominates over debt service risk
Inferred
Agent_Inference
interest_rate_sensitivity
Low absolute debt levels mean 20% rate increase adds limited incremental interest expense; primary sensitivity is via higher discount rates compressing biotech valuations
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Chinese API/raw material sourcing and Taiwan Strait shipping lanes represent top two geopolitical chokepoints for biologics inputs
Inferred
Agent_Inference
international_expansion_readiness
Revenue concentrated in China/Asia-Pacific; RMB managed float limits acute devaluation risk but regulatory capital controls constrain repatriation
Inferred
Agent_Inference
geographic_footprint
Primarily China-domiciled operations with secondary exposure in Southeast Asia; limited USD/EUR revenue hedging reported
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Biotech-grade reagent and CRO/CMO suppliers likely concentrated; single CMO dependency probable given scale, representing potential >30% input cost concentration
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption risk moderate; core biotech R&D and lab operations are on-premise; cloud-hosted data/analytics could face 30-day migration challenge
Inferred
Agent_Inference
business_model_type_secondary
Secondary digital or SaaS-adjacent tools could be disrupted; however core wet-lab IP and regulatory filings are not cloud-dependent
Inferred
Agent_Inference
switching_cost_profile
Moderate API/software coupling risk; proprietary assay platforms and CRO integrations create switching friction but are not fully locked-in
Inferred
Agent_Inference
howey_test_risk_index
Revenue from product sales and licensing does not constitute a securities offering; Howey Test risk is low for primary biotech revenue model
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Chinese patient genomic data subject to PIPL/DSL; GDPR exposure limited but material if EU clinical trials conducted; CCPA risk minimal given negligible US retail presence
Inferred
Agent_Inference
antitrust_exposure_flag
Small market share in fragmented biotech sector; no dominant platform position; antitrust exposure is low
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Primarily transactional/milestone-based; recurring licensing royalties estimated <20% of revenue; majority is project, grant, or product-sale driven
Inferred
Agent_Inference
monetization_vector
Product sales of biotech reagents/kits and contract research services; supplemented by licensing milestones and government grants
Inferred
Agent_Inference
pricing_architecture
Cost-plus pricing typical for CRO/reagent segment; limited pricing power under buyer pressure; stress scenario of 10% price decline materially compresses thin margins
Inferred
Agent_Inference
pricing_power_rating
Low-to-moderate; commodity-adjacent biotech reagents face generic competition; branded assay kits have modest premium but are substitutable
Inferred
Agent_Inference
target_gross_margin_bracket
66.1% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
Free-rider leakage low; products are consumable and proprietary; however academic/government buyers may substitute with open-source alternatives
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is largely headcount-linear given R&D and lab-services nature; doubling revenue likely requires ~70-80% headcount increase
Inferred
Agent_Inference
marginal_cost_of_growth
Suboptimal scalability; biotech services and R&D are labor- and materials-intensive; marginal cost of growth remains high relative to SaaS peers
Inferred
Agent_Inference
franchise_compliance_risk
No franchise network; not applicable to this company's operating model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely rises as addressable institutional buyers saturate; LTV/CAC ratio under pressure without geographic or product-line expansion
Inferred
Agent_Inference
network_effect_present
Minimal direct network effects; proprietary data assets could create indirect data network effects over time but currently weak
Inferred
Agent_Inference
asset_efficiency_ratio
-140.2% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 3 recession sensitivity; discretionary CRO and research spending cut in downturns; government/grant revenue provides partial buffer
Inferred
Agent_Inference
customer_segment_primary
Academic institutions and government research bodies represent primary customer segment; concentration risk moderate given grant-cycle dependency
Inferred
Agent_Inference
customer_segment_secondary
Pharmaceutical and biotech companies as secondary segment; concentration risk elevated if top 3 pharma clients represent >40% of commercial revenue
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0000895464
High
SEC-EDGAR
ticker
YBGJ
High
SEC-EDGAR